Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Medicine. Poisonous contacts.

Kogan SC.

Science. 2010 Apr 9;328(5975):184-5. doi: 10.1126/science.1189198. No abstract available.

PMID:
20378808
2.

Arsenic trioxide controls the fate of the PML-RARalpha oncoprotein by directly binding PML.

Zhang XW, Yan XJ, Zhou ZR, Yang FF, Wu ZY, Sun HB, Liang WX, Song AX, Lallemand-Breitenbach V, Jeanne M, Zhang QY, Yang HY, Huang QH, Zhou GB, Tong JH, Zhang Y, Wu JH, Hu HY, de Thé H, Chen SJ, Chen Z.

Science. 2010 Apr 9;328(5975):240-3. doi: 10.1126/science.1183424. Erratum in: Science. 2010 May 21;328(5981):974.

3.

Marked for death.

Petrie K, Zelent A.

Nat Cell Biol. 2008 May;10(5):507-9. doi: 10.1038/ncb0508-507. No abstract available.

PMID:
18454129
4.

The role of PML in hematopoietic and leukemic stem cell maintenance.

Nakahara F, Weiss CN, Ito K.

Int J Hematol. 2014 Jul;100(1):18-26. doi: 10.1007/s12185-014-1518-x. Epub 2014 Feb 1. Review.

5.

How acute promyelocytic leukaemia revived arsenic.

Zhu J, Chen Z, Lallemand-Breitenbach V, de Thé H.

Nat Rev Cancer. 2002 Sep;2(9):705-13. Review.

PMID:
12209159
6.

Acute promyelocytic leukemia: new issues on pathogenesis and treatment response.

Vitoux D, Nasr R, de The H.

Int J Biochem Cell Biol. 2007;39(6):1063-70. Epub 2007 Mar 21. Review.

PMID:
17468032
7.

Sweet fruit from a poisonous kiss.

Liu D.

J Hematol Oncol. 2010 May 28;3:19. doi: 10.1186/1756-8722-3-19. No abstract available.

8.

Central nervous system relapse in a patient with acute promyelocytic leukaemia treated with arsenic tri-oxide.

Mathews V, Balasubramanian P, Shaji RV, George B, Chandy M, Srivastava A.

Br J Haematol. 2001 Apr;113(1):257-8. No abstract available.

PMID:
11360894
9.

Guest editorial: acute promyelocytic leukemia: change from "highly fatal to highly curable" leukemia.

Komatsu N.

Int J Hematol. 2014 Jul;100(1):16-7. doi: 10.1007/s12185-014-1604-0. Epub 2014 Jun 10. No abstract available.

PMID:
24912657
10.

[Molecular basis of arsenic action in promyelocytic leukemia cells].

Wysocki R, Wiśniewska E.

Postepy Biochem. 2002;48(2):121-30. Review. Polish. No abstract available.

PMID:
12362602
11.

Mobilization of PML/RARalpha negative peripheral blood stem cells with a combination of G-CSF and CXCR4 blockade in relapsed acute promyelocytic leukemia pre-treated with arsenic trioxide.

Stölzel F, Wermke M, Röllig C, Thiede C, Platzbecker U, Bornhäuser M.

Haematologica. 2010 Jan;95(1):171-2. doi: 10.3324/haematol.2009.016568. Epub 2009 Oct 8. No abstract available.

12.

RNF4 is a poly-SUMO-specific E3 ubiquitin ligase required for arsenic-induced PML degradation.

Tatham MH, Geoffroy MC, Shen L, Plechanovova A, Hattersley N, Jaffray EG, Palvimo JJ, Hay RT.

Nat Cell Biol. 2008 May;10(5):538-46. doi: 10.1038/ncb1716. Epub 2008 Apr 13.

PMID:
18408734
13.

Role of SUMO in RNF4-mediated promyelocytic leukemia protein (PML) degradation: sumoylation of PML and phospho-switch control of its SUMO binding domain dissected in living cells.

Percherancier Y, Germain-Desprez D, Galisson F, Mascle XH, Dianoux L, Estephan P, Chelbi-Alix MK, Aubry M.

J Biol Chem. 2009 Jun 12;284(24):16595-608. doi: 10.1074/jbc.M109.006387. Epub 2009 Apr 20.

14.

Resistance to therapy in acute promyelocytic leukemia.

Lehmann-Che J, Bally C, de Thé H.

N Engl J Med. 2014 Sep 18;371(12):1170-2. doi: 10.1056/NEJMc1409040. No abstract available.

15.

PML nuclear bodies mediate the therapeutic response of APL cells.

[No authors listed]

Cancer Discov. 2014 Mar;4(3):OF20. doi: 10.1158/2159-8290.CD-RW2014-019. Epub 2014 Jan 23.

16.

Arsenic trioxide, a therapeutic agent for APL.

Zhang TD, Chen GQ, Wang ZG, Wang ZY, Chen SJ, Chen Z.

Oncogene. 2001 Oct 29;20(49):7146-53. Review.

17.

Resistance to arsenic therapy in acute promyelocytic leukemia.

Zhu HH, Qin YZ, Huang XJ.

N Engl J Med. 2014 May 8;370(19):1864-6. doi: 10.1056/NEJMc1316382. No abstract available.

18.

Arsenic--new life for an old potion.

Gallagher RE.

N Engl J Med. 1998 Nov 5;339(19):1389-91. No abstract available.

PMID:
9801402
19.

APL, a model disease for cancer therapies?

de Thé H, Chelbi-Alix MK.

Oncogene. 2001 Oct 29;20(49):7136-9. Review. No abstract available.

20.

Curing APL: differentiation or destruction?

Kogan SC.

Cancer Cell. 2009 Jan 6;15(1):7-8. doi: 10.1016/j.ccr.2008.12.012.

Supplemental Content

Support Center